Cistoadenoma Seroso De Pâncreas. Por Que a Acurácia É Baixa Aos Exames De Imagem?

Amico, Ênio Campos; Salgado, Caio Trajano Siqueira; Emerenciano, Luisa Maciel; Filho, Guilherme Augusto Santos Ferreira; Alves, José Roberto; Souza, Luiz Eduardo Oliveira Forte Ferreira de; Silva, José Sandro Pereira da

doi:10.1590/0102-672020210002e1640

Cited by 8 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to its atypical morphology, especially concerning unilocular and macrocystic SCN, it has been frequently misdiagnosed as other cystic lesions. In 27 cases studied by Amico et al, 10 patients underwent surgery based on suspicion of MCN (seven cases), IPMN (two cases) and cancer (one case) [ 50 ].…”

Section: Scnmentioning

confidence: 99%

Rare Non-Neuroendocrine Pancreatic Tumours

Mormul

Włoszek

Nowoszewska

et al. 2023

Cancers

View full text Add to dashboard Cite

The most common tumour of the pancreas is ductal adenocarcinoma (PDAC). It remains one of the most lethal non-neuroendocrine solid tumours despite the use of a multi-approach strategy. Other, less-common neoplasms, which are responsible for 15% of pancreatic lesions, differ in treatment and prognosis. Due to the low incidence rate, there is a lack of information about the rarest pancreatic tumours. In this review, we described six rare pancreatic tumours: intraductal papillary mucinous neoplasm (IPMN), mucinous cystadenoma (MCN), serous cystic neoplasm (SCN), acinar cell carcinoma (ACC), solid pseudopapillary neoplasm (SPN) and pancreatoblastoma (PB). We distinguished their epidemiology, clinical and gross features, covered the newest reports about courses of treatment and systematised differential diagnoses. Although the most common pancreatic tumour, PDAC, has the highest malignant potential, it is still essential to properly classify and differentiate less-common lesions. It is vital to continue the search for new biomarkers, genetic mutations and the development of more specific biochemical tests for determining malignancy in rare pancreatic neoplasms.

show abstract

Section: Scnmentioning

confidence: 99%

Rare Non-Neuroendocrine Pancreatic Tumours

Mormul

Włoszek

Nowoszewska

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…Walter de Biase SILVA-NETO 1 , Claudemiro QUIRESE 1 , Eduardo Guimarães Horneaux de MOURA 2 , Fabricio Ferreira COELHO 3 , Paulo HERMAN 3 ABSTRACT -Background: The treatment of choice for patients with schistosomiasis with previous episode of varices is bleeding esophagogastric devascularization and splenectomy (EGDS) in association with postoperative endoscopic therapy. However, studies have shown varices recurrence especially after long-term follow-up.…”

Section: A Queda Da Pressão Portal Após Desvascularização Esofagogást...mentioning

confidence: 99%

“…CT, magnetic resonance imaging (MRI) and magnetic resonance cholangiopancreatography, positron emission tomography (PET), and PET superseded by fused imaging with CT (PET/CT) are the radiological modalities more frequently used to image pancreatic cysts 1,24 . Once pancreatic lesions are detected on CT or MRI, endoscopic ultrasound (EUS) can also be used for further characterization, as it is a valuable tool for showing internal structures such as septa and mural nodules 15 .…”

Section: Introductionmentioning

confidence: 99%

Cystic Pancreatic Lesions: Imaging Versus Anatomopathological Findings-How to Improve Diagnostic Accuracy?

Vieira¹,

Souza²,

Kerche

2023

ABCD, arq. bras. cir. dig.

View full text Add to dashboard Cite

BACKGROUND: Pancreatic cystic lesions are a group of pancreatic neoplasms with different behavior and risk of malignancy. Imaging diagnosis and differentiation of these lesions remain a challenge. AIMS: The aim of this study was to evaluate the agreement between computed tomography and/or magnetic resonance imaging and post-operative pathologic diagnoses of Pancreatic cystic lesions in a University Hospital of São Paulo State. METHODS: A total of 39 patients with surgically diagnosed Pancreatic cystic lesions were enrolled, as a study cohort from 2009 to 2019. Preoperative radiological and final pathological diagnosis was correlated to measure computed tomography and/or magnetic resonance imaging diagnostic. Pancreatic adenocarcinoma, choledochal pancreatic cyst, mucinous cystadenoma, serous cystadenoma, intraductal papillary mucinous neoplasms, and pancreatic pseudocyst were classified as neoplastic cysts. RESULTS: It was noted that 27 patients (69.23%) had preoperative computed tomography and magnetic resonance imaging, 11 patients (28.20%) had preoperative computed tomography only, and 1 patient had preoperative magnetic resonance imaging only. The values for diagnoses made only with computed tomography (p=0.47) and from the combination of computed tomography+magnetic resonance imaging (p=0.50) did also point to moderate agreement with the anatomopathological findings. The values pointed to a fair agreement for the diagnosis of mucinous cystadenoma (p=0.3), moderate agreement for intraductal papillary mucinous neoplasms (p= 0.41), good agreement for serous cystadenoma (p=0.79), and excellent agreement for choledochal pancreatic cyst (p=1), pancreatic pseudocyst (p=0.84), and Frantz tumor (p=1) (p<0.05). CONCLUSIONS: The findings of computed tomography and/or magnetic resonance imaging have an equivalent diagnostic agreement with an anatomopathological diagnosis for differentiating benign from malignant Pancreatic cystic lesions and in suggesting a specific diagnosis. There is no statistical difference between the use of computed tomography alone and computed tomography+magnetic resonance imaging in the improvement of diagnostic accuracy.

show abstract

“…The atypical morphological presentations of serous cystadenoma of the pancreas may be the main cause for surgical indication in these patients 4,5 . MRI can be a helpful adjunct for discrimination of serous cystadenoma of the pancreas from pancreatic malignancy 4 . 68 Ga-FAPI is a novel and promising PET tracer for imaging of pancreatic malignancy 6,7 .…”

mentioning

confidence: 99%

“…Despite low potential for malignancy, a significant number of patients with serous cystadenoma of the pancreas are still operated on 3. The atypical morphological presentations of serous cystadenoma of the pancreas may be the main cause for surgical indication in these patients 4,5. MRI can be a helpful adjunct for discrimination of serous cystadenoma of the pancreas from pancreatic malignancy.4 68 Ga-FAPI is a novel and promising PET tracer for imaging of pancreatic malignancy 6,7.…”

mentioning

confidence: 99%

Serous Cystadenoma of the Pancreas Showing Increased Uptake on 68Ga-FAPI PET/CT

Zhao

Meng

et al. 2022

Clin Nucl Med

View full text Add to dashboard Cite

Serous cystadenoma of the pancreas is a type of pancreatic cystic neoplasm frequently found in clinical practice. Serous cystadenoma of the pancreas can have a varied morphological presentation on imaging examinations. Therefore, it is sometimes very challenging to differentiate serous cystadenoma of the pancreas from pancreatic malignancy. In this study, we present a case of serous cystadenoma of the pancreas showing focally elevated radiotracer uptake on 68Ga-FAPI PET/CT. Considering potential future clinical use of 68Ga-FAPI PET/CT in malignancy, awareness of the false-positive findings is important for the differential diagnosis and management of these lesions.

show abstract

Cistoadenoma Seroso De Pâncreas. Por Que a Acurácia É Baixa Aos Exames De Imagem?

Cited by 8 publications

References 26 publications

Rare Non-Neuroendocrine Pancreatic Tumours

Rare Non-Neuroendocrine Pancreatic Tumours

Cystic Pancreatic Lesions: Imaging Versus Anatomopathological Findings-How to Improve Diagnostic Accuracy?

Serous Cystadenoma of the Pancreas Showing Increased Uptake on 68Ga-FAPI PET/CT

Contact Info

Product

Resources

About